 | |
| Clinical data | |
|---|---|
| Trade names | Tornalate |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a601236 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | 2–5 minutes |
| Duration of action | 6–8 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H31NO5 |
| Molar mass | 461.558 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
Bitolterol mesylate, formerly sold under the brand nameTornalate, is a short-actingβ2-adrenergic receptor agonist used for the relief ofbronchospasm in conditions such asasthma[1][2] andchronic obstructive pulmonary disease (COPD).[3][4][5] Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.
Bitolterol is aprodrug ofcolterol.[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.[8]The drug, alone or in co-administration withtheophylline, doesn't show cardiotoxic effect.[9]
The USFood and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market byÉlan Pharmaceuticals in 2001.
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
